Indefinite Delivery Contract 36E79720D0016
Award Date
3/15/20
Last Date to Order
3/15/21
Federal Agency
National Acquisition Center
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs National Acquisition Center awarded an indefinite delivery contract to Seqirus USA Inc. to deliver influenza virus vaccines for the 2022-2023 season to the VA, Federal Bureau of Prisons, Indian Health Service, and James A. Lovell Federal Health Care Center. Task orders under the contract, with a potential value of $69,190,924.13, provide vaccines including 10-dose vials, single dose syringes in boxes of 10, and an adjuvant vaccine for individuals aged 65 and...
The Department of Veterans Affairs National Acquisition Center awarded an indefinite delivery contract to Sanofi Pasteur Inc. for the supply of influenza vaccines. Task orders issued by VA, Federal Bureau of Prisons, Indian Health Service, and Department of Health and Human Services procure influenza virus vaccines in pre-filled syringes and multi-dose vials for individuals over 18 years old. Additional line items provide syringes tailored for those 65 and older as well as children ages 36...
This federal contract IDV award to Glaxosmithkline, LLC from the Department of Veterans Affairs (VA) National Acquisition Center procures influenza vaccines for use by the VA, Bureau of Prisons (BOP), Indian Health Service (IHS), and Captain James A. Lovell Federal Health Care Center. The contract has a total estimated annual usage of 306,829 vaccine doses across various product types including 10-dose vials, pre-filled pediatric syringes, and pre-filled syringes for adults 36 months and...
The Department of Veterans Affairs National Acquisition Center awarded a single award IDV to Seqirus USA Inc. on March 15, 2021 with a potential value of $67,604,685.53. Task orders issued against the IDV by the VA, Bureau of Prisons, Indian Health Service, and James A. Lovell Federal Healthcare Center procure influenza virus vaccines for the 2021-2022 season. Vaccines provided under the IDV and related task orders include those in multi-dose vials and single dose syringes for adults and...
The Defense Logistics Agency Troop Support Medical awarded an indefinite delivery contract to Glaxosmithkline, LLC to supply influenza virus vaccinations. Delivery orders issued against this vehicle total over $44.5 million and require Glaxosmithkline to provide vaccines from its Research Triangle Park, North Carolina facility. Performance periods range from March 2021 to November 2021. No set-asides or subcontractors are specified. This contract aims to ensure U.S. armed forces and DLA...
The Defense Logistics Agency Troop Support Medical awarded an Indefinite Delivery Contract to Glaxosmithkline, LLC with a potential value of $50,705,424.00 to supply influenza virus vaccines. Under this contract, three firm fixed price delivery orders were issued for a total of $33,803,616.00 to provide vaccines from Glaxosmithkline's facility in Research Triangle Park, North Carolina. The periods of performance for the delivery orders range from August 31, 2022 through February 24, 2023. The...
The federal contract IDV award is for the procurement of influenza virus vaccines for the 2024-2025 flu season. The prime contractor is Sanofi Pasteur Inc., a foreign-owned, for-profit manufacturer of pharmaceutical goods. This award is being made by the U.S. Department of Veterans Affairs (VA) National Acquisition Center and will be used to supply vaccines to the VA, State Veteran Homes, Bureau of Prisons, Indian Health Service, and Captain James A. Lovell Federal Health Care Center. The...
This federal contract IDV award from the National Acquisition Center, a civilian agency, is for the procurement of influenza virus vaccines for the 2025-2026 flu season. The prime contractor, Seqirus USA Inc., a foreign-owned, for-profit manufacturer, will deliver various influenza vaccine formulations including quadrivalent vaccines, multi-dose vials, pre-filled syringes, and specialized high-dose vaccines for different age groups and populations. The contract has a ceiling value of...
The Centers for Disease Control and Prevention awarded an indefinite delivery contract to Glaxosmithkline, LLC for adult influenza vaccines. The contract has a potential value of $13.41 million to supply a minimum of 100 doses and maximum of 20 million doses of inactivated influenza vaccine for individuals aged 19 years and older through February 28, 2023. Vaccines must be licensed by the FDA and manufactured in compliance with cGMP regulations. Delivery locations include CDC distribution...
The Indefinite Delivery Contract (IDC) awarded to Sanofi Pasteur Inc. by the National Acquisition Center, a component of the Department of Veterans Affairs (VA), is for the procurement of Influenza Virus Vaccine for the 2025-2026 influenza season. The contract has a Period of Performance from March 15, 2025 to March 14, 2026, and a ceiling value of $113,670.50. As the prime contractor, Sanofi Pasteur Inc. will provide seasonal influenza vaccines to support requirements for the VA, State...
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Completion Date (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
Delivery Order 36E79720D0016-36C26220F0331 | Glaxosmithkline, LLC | $347.4k | 4/7/20 | 3/31/21 | 4/7/20 | |
Delivery Order 36E79720D0016-36C24120F0174 | Glaxosmithkline, LLC | $105.5k | 4/3/20 | 10/31/20 | 4/3/20 | |
Delivery Order 36E79720D0016-36C24520F0443 | Glaxosmithkline, LLC | $192.3k | 4/3/20 | 10/15/20 | 4/3/20 | |
Delivery Order 36E79720D0016-36C24520F0463 | Glaxosmithkline, LLC | $43.9k | 4/10/20 | 10/15/20 | 4/10/20 | |
Delivery Order 36E79720D0016-36C24120F0267 | Glaxosmithkline, LLC | $24.8k | 8/14/20 | 12/15/20 | 8/14/20 |